-Roche is buying Innovatis, a privately- held company based in Germany for EUR 15M. Innovatis provides “automated cell analysis solutions”, focusing on cell counting, viability testing and cell function analysis in research, as well as bioproduction. Roche has been one of Innovatis’ biggest clients over the last several years and will now become part of Roche Applied Science. [PharmaTimes]

-SFJ Pharmaceuticals raised $45M in Series A from Abingworth Management and Clarus Ventures. The company brings U.S. and European drugs to Japan for development and commercialization and will use its new funding to make its first acquisitions. [peHUB]

-NKT Therapeutics announced that it received $8M in venture financing from SV Life Sciences and MedImmune Ventures. NKT is developing an antibody that targets the invariant T cell receptor which, depending on the effector function of the antibody, can either activate or deplete NKT cells. NKT plans to target asthma as well as cancer, autoimmune diseases, atopic dermatitis and vaccine adjuvants. [Xconomy]

-Numerate, a drug engineering company, raised $5.5M in a Series B from Foundation Capital and Lanza TechVentures. [peHUB]

-IGI Laboratories (AMEX: IG) has completed a $6M private placement (PIPE) of Series B-1 Convertible Preferred Stock, secured convertible promissory notes and warrants to purchase shares of Series B-2 Preferred Stock from Signet Healthcare Partners. IGI is a publicly traded company (AMEX) that provides topical formulation development, analytical, manufacturing and packaging services. [The Earth Times]

-PuraMed Biosciences has raised an undisclosed amount. of funding. PuraMed operates in the OTC consumer market and makes LipiGesic M, a feverfew-based product for the treatment of migraine. [BusinessWire]

Image from sitewizard

Related Posts